Skip to content
Search

Latest Stories

Follow Us:
Top Stories

Bill of the month: Limiting Chinese influence in the biotech sector

WuXi AppTec building

The BIOSECURE Act takes direct aim at five Chinese companies, including WuXi AppTec.

CFOTO/Future Publishing via Getty Images

Rogers is the “data wrangler” at BillTrack50. He previously worked on policy in several government departments.

This month IssueVoter and BillTrack50 take a look at the BIOSECURE Act, a significant escalation in efforts to restrict Chinese influence in America's biotechnology sector.

The bipartisan legislation, passed by the House of Representatives in September and spearheaded by Reps. Brad Wenstrup (R-Ohio) and Raja Krishnamoorthi (D-Ill.), aims to protect American patient data and prevent federal funds from flowing to biotechnology companies deemed to pose national security risks.


Key Provisions

At its core, the BIOSECURE Act seeks to create a firewall between federal agencies and certain biotechnology companies. Under the legislation, federal agencies would be barred from contracting with designated "biotechnology companies of concern" or providing grants and loans to entities that use their services.

This prohibition extends to organizations that maintain contracts with these companies, creating a ripple effect throughout the biotechnology supply chain.

The bill takes direct aim at five Chinese companies: BGI, MGI, Complete Genomics, WuXi AppTec,and WuXi Biologics. Beyond these specific designations, it establishes a framework for identifying additional companies as security risks, particularly those controlled by "foreign adversaries" including China, Russia, North Korea, Iran and Cuba.

Weaponizing Our Genome

Supporters of the BIOSECURE Act, with Wenstrup at the forefront, paint a concerning picture of vulnerable national security and compromised patient privacy.

As Krishnamoorthi dramatically frames the issue: "As Americans have their blood drawn or take other medical tests each day, few have any idea that their personal genetic information could be going to biotech companies controlled by the Chinese Communist Party and other adversaries that would weaponize our own genomes against us."

The military connections between Chinese biotech firms and the People's Liberation Army have raised additional red flags. These relationships reportedly extend beyond mere collaboration to include joint research projects and shared genetic collection sites. The fact that WuXi AppTec derives over 60 percent of its revenue from the U.S. market has intensified concerns about American dependency on potentially compromised supply chains.

Perhaps most alarming to supporters is China's legal framework requiring companies to share data with the government upon request. This mandate creates a direct pipeline for sensitive genetic information about American citizens to flow into the hands of Chinese authorities.

Opposition and Concerns

Yet the legislation has drawn significant criticism, even from unexpected quarters. Rep. Jim McGovern (D-Mass.), known for his tough stance on China, has emerged as a prominent critic. In his forceful opposition to the bill, McGovern argues: "Naming specific companies will create a 'whack-a-mole' situation where entities can change their name and reincorporate to evade sanctions. ... [I]t's totally wrong to call out specific companies without any formal investigation or interagency process —that might be how they do things in the PRC, but this is the United States of America where we ought to have a thorough, independent investigation."

Company Responses

Health care technology executives have added their voices to the chorus of concern. At the Clinical Trial Supply West Coast 2024 conference, Umar Hayat of Gladius Therapeutics offered a stark warning:"This seems more like politics rather than about a security threat. ... [I]f you want to play politics, play politics in other industries like automotive, electronics or telecommunications. Don't play politics in health care where so many people are in dire need. Let science evolve and advance — wherever it comes from."

BGI has mounted a vigorous defense against the allegations, emphasizing that it maintains no direct patient services in the United States and therefore has no access to Americans' personal data. The company has clarified that its Covid-19 PCR testing analyzes only viral RNA, not patient DNA, and stressed its status as a privately owned entity independent from Chinese government control. BGI likens its gene bank operations to those of U.S. national laboratories, suggesting that fears about its activities may be overblown.

Broader Implications

The BIOSECURE Act represents more than a simple regulatory change; it signals a fundamental shift in how the United States approaches biotechnology in the context of national security. This transformation raises complex questions about the future of international scientific collaboration at a time when global cooperation has proven crucial for addressing health challenges.

The legislation could trigger a significant reorganization of pharmaceutical supply chains, with countries like Ireland and India potentially emerging as alternative manufacturing locations. However, this restructuring comes with its own set of challenges and uncertainties.

Innovation in the biotechnology sector could face headwinds as restrictions on collaboration with Chinese firms affect the development pipeline for new treatments. The legislation also adds another layer of complexity to U.S.-China relations, potentially complicating ongoing dialogue in other areas.

Looking Ahead

As the BIOSECURE Act moves to the Senate with strong bipartisan support, its passage could mark a watershed moment in U.S. biotechnology policy. Policymakers face the delicate task of balancing legitimate national security concerns with the benefits of international scientific collaboration and market competition.

The debate over this legislation reflects deeper questions facing the biotechnology sector about the relationship between national security and scientific progress. How nations protect sensitive genetic data while maintaining scientific openness, and the role of national security considerations in health care innovation, will likely shape the future of global biotechnology development for years to come.

The answers to these questions will determine not just the future of U.S.-China relations in biotechnology, but the pace and direction of medical innovation in an increasingly interconnected world.


Read More

Pacific heights , San Francisco, CA

High view over Pacific heights and San Francisco Bay at sunset

Getty Images

Class A for Residents, Class B for Investors

Neighborhood residents should be able to build ownership without surrendering control to whoever brings the largest check. I propose a neighborhood corporation with Class A shares for residents and Class B shares for outside investors. Pacific Heights and Cow Hollow could examine the first model, then make its documents and lessons available to other neighborhoods.

The distinction must mean something. Class A would protect resident governance. Class B would let outside capital participate on disclosed economic terms. The corporation would own assets it voluntarily acquires and operate agreed services. It would govern those assets and contracts; government authority over zoning, taxes and public streets would remain subject to public law.

Keep ReadingShow less
​A demonstrator holds a sign

A demonstrator holds a sign in front of the Federal Courthouse in Detroit, Michigan.

(Photo by Bill Pugliano/Getty Images)

Beyond Airstrikes: Why America Must Rethink Its Counterterrorism Strategy in Nigeria

When American forces carried out airstrikes against suspected Islamic State militants in northwest Nigeria on Christmas Day 2025, the operation offered a glimpse of renewed security cooperation between Washington and Abuja. But for Nigerians living in communities threatened by terrorism, kidnapping and armed attacks, a more pressing question remained: Would the strikes make their lives any safer?

That question deserves attention in Washington. The United States has spent decades helping Nigeria combat terrorism through military equipment, intelligence sharing and training. Yet armed violence continues to disrupt everyday life across northern Nigeria, raising doubts about how the success of American counterterrorism assistance should be measured.

Keep ReadingShow less
Victorian style houses at Alamo Square in San Francisco, CA

Colourful vibrant Victorian style houses at Alamo Square in San Francisco, California, USA

Getty Images

Fund the Community DataBank

San Francisco residents need an organization that can follow public money and decisions before the damage is done. I propose a Community DataBank, beginning with Pacific Heights and Cow Hollow, supported by a modest, publicly approved allocation of our taxes. Residents should be able to find out what government is doing without requiring everyone to research City Hall.

My earlier proposal placed two desks outside the Mayor’s Office, staffed by neighborhood association members who would watch who goes in and out and follow the public business behind those visits. The DataBank would give those desks useful work and reliable records. A visitor’s presence would prompt a question; official documents would establish what actually happened.

Keep ReadingShow less
US America and China flags on chess king on a chessboard.

USA and China trade relations, cooperation strategy. US America and China flags on chess king on a chessboard.

Getty Images

America’s Gridlock Is Beijing’s Best Argument

Americans tend to treat democracy’s superiority as settled, and the long-run evidence backs them up. A major study by MIT economist Daron Acemoglu and colleagues found that countries that democratize end up about 20 percent richer per person within a generation. But most of the world does not grade governments on long-run studies. For billions of people outside the wealthy West, the test is simpler: does the power stay on, are food prices steady, is there work, and do the roads get built? When the stomach is empty, a ballot can feel like a luxury.

China understands this and sells its model on exactly those terms. Its GDP per capita has climbed from about $300 in 1980 to nearly $15,000 today, by IMF figures, and the World Bank credits it with lifting some 800 million people out of extreme poverty. India, the world’s largest democracy, started from a similar place and sits near $2,800. Beijing’s centralized system, paired with Deng Xiaoping’s market reforms, built power plants, factories and rail lines at a pace India’s more deliberative politics has not matched. Anyone who values liberty will find little to admire in that model. It does explain why the model sells.

Keep ReadingShow less